Cure My Disease

Don't miss your cure!

 Log in / Sign up

Pharmacy-Based PrEP could transform HIV prevention for young women in tanzania

NCT ID NCT07687888

Prevention Sponsor: Mzumbe University - Centre of Excellence in Health Monitoring and Evaluation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 07, 2026 · Last updated Jul 23, 2026 · Updated 3 times

Summary

This study explores whether offering HIV prevention medication (PrEP) through pharmacies can help more young women aged 18-24 in Tanzania access and consistently use it. Researchers compare four different pharmacy-based service models to standard care, and later test cost-sharing approaches to improve long-term sustainability. The goal is to find practical ways to reach young women who may not otherwise get PrEP.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PrEP (pre-exposure prophylaxis) and HIV self-test kits
What this could lead to
If successful, this could make HIV prevention more accessible and sustainable for young women in Tanzania through pharmacy-based services.
What could go wrong
This is an implementation study, not a test of PrEP's effectiveness. Results may not apply to other regions or populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 2,818 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 24 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria (Parent study: YW cohort study): 1. Female sex; 2. Age 18-24 at the baseline visit; 3. Living in one of five study sites in Shinyanga, Geita or Kagera regions of Tanzania with no known plans to move; 4. Interested in starting PrEP; 5. Access to a mobile phone (either own phone or borrowed phone); and 6. Eligible for PrEP based on Tanzania National PrEP Guidelines behavioral screening criteria Exclusion Criteria: Currently taking PrEP (refilled a PrEP prescription within the past 28 days at enrollment). Inclusion Criteria (Sub-study: YW household survey): 1. Female sex; 2. Age 18-24; and 3. Living in one of five study sites in Shinyanga, Geita or Kagera regions of Tanzania. Exclusion Criteria (Sub-study: YW household survey): N/A Inclusion Criteria (Study pharmacies): 1. Geographically located within one of five study sites in Shinyanga, Geita or Kagera regions of Tanzania; 2. Located within 4 km of at least 1 health facility that provides PrEP services and whose lab conducts creatinine and hepatitis B testing; 3. Has no planned extended closures over the next 24 months. Exclusion Criteria (Study pharmacies): N/A Inclusion Criteria (Sub-study: Pharmacy staff): 1. Pharmacy owners and staff affiliated with study pharmacies; and 2. ≥18 years of age. Exclusion Criteria (Sub-study: Pharmacy staff): N/A Inclusion Criteria (Sub-study: Stakeholders): 1. Staff employed at referral health facilities within one of five study sites in Shinyanga, Geita or Kagera regions of Tanzania or local, regional, or national government officials; 2. ≥18 years of age. Exclusion Criteria (Sub-study: Stakeholders): N/A

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

posterior leukoencephalopathy syndrome HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV PREP

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Health for a Prosperous Nation

    Dar es Salaam, Tanzania

More trials for these conditions

Other studies related to the condition(s) this trial covers.